Dominic B Rowe

List of Publications by Year
in descending order

80 papers	5,364 citations	136940 32 h-index	91872 69 g-index
85 all docs	85 docs citations	85 times ranked	7874 citing authors

#	Article	IF	Citations
1	Polygenic risk score analysis for amyotrophic lateral sclerosis leveraging cognitive performance, educational attainment and schizophrenia. European Journal of Human Genetics, 2022, 30, 532-539.	2.8	16
2	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 2022, 14, eabj0264.	12.4	38
3	NEK1 and STMN2 short tandem repeat lengths are not associated with Australian amyotrophic lateral sclerosis risk. Neurobiology of Aging, 2022, , .	3.1	0
4	Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. Journal of Medical Genetics, 2021, 58, 87-95.	3.2	48
5	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biology, 2021, 22, 90.	8.8	49
6	Coexisting Lewy body disease and clinical parkinsonism in amyotrophic lateral sclerosis. European Journal of Neurology, 2021, 28, 2192-2199.	3.3	6
7	Genetic analysis of GLT8D1 and ARPP21 in Australian familial and sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2021, 101, 297.e9-297.e11.	3.1	6
8	Genetic Analysis of Tryptophan Metabolism Genes in Sporadic Amyotrophic Lateral Sclerosis. Frontiers in Immunology, 2021, 12, 701550.	4.8	8
9	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
10	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurology, The, 2020, 19, 71-80.	10.2	94
11	Neuronal intranuclear inclusion disease is genetically heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 1716-1725.	3.7	38
12	Genome-wide Meta-analysis Finds the ACSL5-ZDHHC6 Locus Is Associated with ALS and Links Weight Loss to the Disease Genetics. Cell Reports, 2020, 33, 108323.	6.4	41
13	Identity by descent analysis identifies founder events and links SOD1 familial and sporadic ALS cases. Npj Genomic Medicine, 2020, 5, 32.	3.8	20
14	Metabolite Profiling Reveals Predictive Biomarkers and the Absence of Î²-Methyl Amino-<scp>l</scp>-alanine in Plasma from Individuals Diagnosed with Amyotrophic Lateral Sclerosis. Journal of Proteome Research, 2020, 19, 3276-3285.	3.7	18
15	Significant out-of-sample classification from methylation profile scoring for amyotrophic lateral sclerosis. Npj Genomic Medicine, 2020, 5, 10.	3.8	25
16	Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 162-171.	1.9	8
17	Diffusion kurtosis and quantitative susceptibility mapping MRI are sensitive to structural abnormalities in amyotrophic lateral sclerosis. NeuroImage: Clinical, 2019, 24, 101953.	2.7	29
18	Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 595-604.	1.7	63

#	Article	IF	Citations
19	Whole genome sequencing for the genetic diagnosis of heterogenous dystonia phenotypes. Parkinsonism and Related Disorders, 2019, 69, 111-118.	2.2	44
20	Predicting Progression in Parkinsonâ€™s Disease Using Baseline and 1-Year Change Measures. Journal of Parkinson's Disease, 2019, 9, 665-679.	2.8	15
21	Monozygotic twins and triplets discordant for amyotrophic lateral sclerosis display differential methylation and gene expression. Scientific Reports, 2019, 9, 8254.	3.3	36
22	Limitations of Electromyography in the Assessment of Abdominal Wall Muscle Contractility Following Botulinum Toxin A Injection. Frontiers in Surgery, 2019, 6, 16.	1.4	11
23	The C9orf72 hexanucleotide repeat expansion presents a challenge for testing laboratories and genetic counseling. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 310-316.	1.7	16
24	Self-reported physical activity levels and clinical progression in early Parkinson's disease. Parkinsonism and Related Disorders, 2019, 61, 118-125.	2.2	53
25	ISQUA18-1466Facing the Challenges of Genetic Testing: Family Member Experiences. International Journal for Quality in Health Care, 2018, 30, 50-50.	1.8	2
26	The Parkinson's progression markers initiative (PPMI) â€“ establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology, 2018, 5, 1460-1477.	3.7	330
27	Inflammasome inhibition prevents Î±-synuclein pathology and dopaminergic neurodegeneration in mice. Science Translational Medicine, 2018, 10, .	12.4	493
28	Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis. Neuropharmacology, 2017, 112, 346-364.	4.1	33
29	Motor neuron disease mortality and lifetime petrol lead exposure: Evidence from national age-specific and state-level age-standardized death rates in Australia. Environmental Research, 2017, 153, 181-190.	7.5	10
30	Predictive genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counselling considerations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 475-485.	1.7	26
31	Cross-ethnic meta-analysis identifies association of the GPX3-TNIP1 locus with amyotrophic lateral sclerosis. Nature Communications, 2017, 8, 611.	12.8	93
32	NONâ€INVASIVE VENTILATION IN MOTOR NEURONE DISEASE/AMYOTROPHIC LATERAL SCLEROSIS: AN AUSTRALASIAN PERSPECTIVE. Respirology, 2017, 22, 40-40.	2.3	0
33	Increased peripheral inflammation in asymptomatic leucineâ€rich repeat kinase 2 mutation carriers. Movement Disorders, 2016, 31, 889-897.	3.9	76
34	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	21.4	494
35	A Temporal Association between Accumulated Petrol (Gasoline) Lead Emissions and Motor Neuron Disease in Australia. International Journal of Environmental Research and Public Health, 2015, 12, 16124-16135.	2.6	9
36	SNCAGene, but NotMAPT, Influences Onset Age of Parkinsonâ€™s Disease in Chinese and Australians. BioMed Research International, 2015, 2015, 1-6.	1.9	16

#	Article	IF	Citations
37	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders, 2015, 30, 919-927.	3.9	244
38	Novel TBK1 truncating mutation in a familial amyotrophic lateral sclerosis patient of Chinese origin. Neurobiology of Aging, 2015, 36, 3334.e1-3334.e5.	3.1	35
39	Association of Cerebrospinal Fluid Î²-Amyloid 1-42, T-tau, P-tau₁₈₁, and Î±-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. JAMA Neurology, 2013, 70, 1277-87.	9.0	318
40	Measurement of LRRK2 and Ser910/935 Phosphorylated LRRK2 in Peripheral Blood Mononuclear Cells from Idiopathic Parkinson's Disease Patients. Journal of Parkinson's Disease, 2013, 3, 145-152.	2.8	44
41	Reduced T helper and B lymphocytes in Parkinson's disease. Journal of Neuroimmunology, 2012, 252, 95-99.	2.3	158
42	The phenotypic spectrum of dystonia in Mohrâ€“Tranebjaerg syndrome. Movement Disorders, 2012, 27, 1034-1040.	3.9	22
43	Adult onset leucodystrophy with neuroaxonal spheroids and pigmented glia (ALSP): report of a new kindred. Neuropathology and Applied Neurobiology, 2012, 38, 95-100.	3.2	6
44	Interaction between Î±-Synuclein and Tau Genotypes and the Progression of Parkinson's Disease. Journal of Parkinson's Disease, 2011, 1, 271-276.	2.8	14
45	Predicting a Positive Response to Intravenous Immunoglobulin in Isolated Lower Motor Neuron Syndromes. PLoS ONE, 2011, 6, e27041.	2.5	13
46	Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. Clinical Neurophysiology, 2010, 121, 1781-1785.	1.5	20
47	Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease?. Movement Disorders, 2009, 24, 833-838.	3.9	56
48	Mitochondrial DNA haplogroups J and K are not protective for Parkinson's disease in the Australian community. Movement Disorders, 2009, 24, 290-292.	3.9	23
49	Anti-melanin antibodies are increased in sera in Parkinson's disease. Experimental Neurology, 2009, 217, 297-301.	4.1	72
50	The phase shift index for marking functional asynchrony in Alzheimer's disease patients using fMRI. Magnetic Resonance Imaging, 2008, 26, 379-392.	1.8	21
51	Haplotype analysis of the IGF2â€INSâ€TH gene cluster in Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 495-499.	1.7	17
52	Novel prion protein gene mutation presenting with subacute PSP-like syndrome. Neurology, 2007, 68, 868-870.	1.1	38
53	VISAâ€"A pass to innate immunity. International Journal of Biochemistry and Cell Biology, 2007, 39, 287-291.	2.8	18
54	A functional polymorphism in the parkin gene promoter affects the age of onset of Parkinson's disease. Neuroscience Letters, 2007, 414, 170-173.	2.1	9

#	Article	IF	Citations
55	Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's Disease. Movement Disorders, 2007, 22, 982-989.	3.9	34
56	Characterizing phase-only fMRI data with an angular regression model. Journal of Neuroscience Methods, 2007, 161, 331-341.	2.5	17
57	Signal and noise of Fourier reconstructed fMRI data. Journal of Neuroscience Methods, 2007, 159, 361-369.	2.5	22
58	Anticipation of onset age in familial Parkinson's disease without SCA gene mutations. Parkinsonism and Related Disorders, 2006, 12, 309-313.	2.2	3
59	Nocturnal hypoxia in motor neuron disease is not predicted by standard respiratory function tests. Internal Medicine Journal, 2006, 36, 419-422.	0.8	3
60	Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. Journal of Neurochemistry, 2005, 95, 599-608.	3.9	28
61	Assessment of disease progression in motor neuron disease. Lancet Neurology, The, 2005, 4, 229-238.	10.2	74
62	A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain, 2005, 128, 2665-2674.	7.6	307
63	Interleukinâ€12 and interferonâ€Î³ are not detectable in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, 5, 118-120.	1.2	12
64	Isolated trochlear nerve palsy as a presenting feature of primary polycythemia rubra vera. Clinical and Experimental Ophthalmology, 2004, 32, 339-340.	2.6	4
65	Genetic contributions to Parkinson's disease. Brain Research Reviews, 2004, 46, 44-70.	9.0	83
66	Helicobacter pylorihiccup. Internal Medicine Journal, 2003, 33, 133-134.	0.8	8
67	Identifying the Pattern of Olfactory Deficits in Parkinson Disease Using the Brief Smell Identification Test. Archives of Neurology, 2003, 60, 545.	4.5	172
68	Eardrop attacks: seizures triggered by ciprofloxacin eardrops. Medical Journal of Australia, 2003, 178, 343-343.	1.7	7
69	An inflammatory review of Parkinsonâ€™s disease. Progress in Neurobiology, 2002, 68, 325-340.	5.7	297
70	Isolated fascicular oculomotor nerve palsy as the initial presentation of the antiphospholipid syndrome. Journal of Clinical Neuroscience, 2002, 9, 691-694.	1.5	13
71	Effects of Cerebrospinal Fluid From Patients With Parkinson Disease on Dopaminergic Cells. Archives of Neurology, 1999, 56, 194.	4.5	46
72	Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sciences, 1999, 64, 1275-1285.	4.3	94

#	Article	IF	Citations
73	Right parietal cortex is involved in the perception of sound movement in humans. Nature Neuroscience, 1998, 1, 74-79.	14.8	251
74	Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. Journal of Neuroscience Research, 1998, 53, 551-558.	2.9	59
75	Neurological abnormalities in familial and sporadic schizophrenia. Brain, 1998, 121, 191-203.	7.6	104
76	Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. Journal of Neuroscience Research, 1998, 53, 551-558.	2.9	3
77	Focal vertebral artery dissection causing Brown-Sequard's syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 415-416.	1.9	37
78	Complications from intra-aortic balloon counterpulsation: a review of 303 cardiac surgical patients. European Journal of Cardio-thoracic Surgery, 1992, 6, 530-535.	1.4	32
79	Comparison of image analysis and flow cytometric determination of cellular DNA content.. Journal of Clinical Pathology, 1991, 44, 147-151.	2.0	21
80	Nonrandom cosmid cloning and prophage SP beta homology near the replication terminus of the Bacillus subtilis chromosome. Journal of Bacteriology, 1986, 167, 379-382.	2.2	5